BioLife Solutions (BLFS) Financials

$22.43 +0.35 (+1.59%)

Closing price 04:00 PM Eastern

Extended Trading

$22.42 -0.02 (-0.07%)

As of 04:47 PM Eastern

Annual Income Statements for BioLife Solutions

This table shows BioLife Solutions' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-3.22	-4.21	-6.88	-2.73	-25	-1.66	1.98	-8.91	-140	-68	-20
Consolidated Net Income / (Loss)	-3.30	-5.00	-8.04	-2.52	-25	-1.66	1.98	-8.91	-140	-68	-20
Net Income / (Loss) Continuing Operations	-3.30	-5.00	-8.04	-2.52	-25	-1.66	1.98	-8.91	0.39	-18	-11
Total Pre-Tax Income	-3.30	-5.00	-8.04	-2.52	-25	-3.20	-1.28	-29	-4.85	-18	-11
Total Operating Income	-3.14	-5.02	-4.85	-1.06	3.66	-0.22	-6.24	-35	-5.92	-23	-7.13
Total Gross Profit	3.04	3.81	4.78	6.75	14	19	27	37	47	46	54
Total Revenue	6.19	6.45	8.23	11	20	27	48	119	76	76	82
Operating Revenue	6.19	6.45	8.23	11	20	27	48	119	76	76	82
Total Cost of Revenue	3.16	2.63	3.45	4.28	6.22	8.76	21	82	29	30	29
Operating Cost of Revenue	3.16	2.63	3.45	4.28	6.22	8.76	21	82	29	30	29
Total Operating Expenses	6.17	8.83	9.63	7.80	9.86	19	34	72	53	69	61
Selling, General & Admin Expense	3.97	4.87	4.59	4.52	5.95	8.89	15	34	33	43	41
Marketing Expense	1.33	2.58	3.01	2.09	2.62	4.70	6.41	14	12	13	9.61
Research & Development Expense	0.87	1.38	2.03	1.19	1.30	3.17	6.72	12	8.67	12	7.91
Amortization Expense	-	-	-	-	0.00	1.08	3.03	8.20	3.99	3.52	2.74
Other Special Charges / (Income)	-	-	-	-	0.00	0.05	1.58	2.88	-4.75	-2.19	0.00
Total Other Income / (Expense), net	-0.17	0.02	-3.19	-1.46	-29	-2.98	4.96	6.13	1.08	4.97	-4.30
Interest & Investment Income	-	0.00	-2.79	-1.01	-0.39	9.87	1.36	5.97	0.41	-1.45	-4.79
Other Income / (Expense), net	0.01	0.02	0.00	-0.11	-28	13	3.60	0.17	0.66	6.42	0.50
Income Tax Expense	-	-	-	0.00	0.00	-1.54	-3.26	-20	-5.24	-0.02	-0.04
Net Income / (Loss) Discontinued Operations	-	-	-	-	-	-	-	-	-140	-50	-8.80
Basic Earnings per Share	($0.31)	($0.35)	($0.54)	($0.21)	($1.56)	($0.09)	$0.07	($0.23)	($3.29)	($1.55)	($0.44)
Weighted Average Basic Shares Outstanding	10.45M	12.18M	12.64M	13.26M	16.26M	19.46M	27.31M	38.50M	42.48M	43.72M	46.07M
Diluted Earnings per Share	($0.31)	($0.35)	($0.54)	($0.21)	($1.56)	($0.09)	($0.06)	($0.23)	($3.25)	($1.55)	($0.44)
Weighted Average Diluted Shares Outstanding	10.45M	12.18M	12.64M	13.26M	16.26M	19.46M	27.31M	38.50M	43.07M	43.72M	46.07M
Weighted Average Basic & Diluted Shares Outstanding	10.45M	12.18M	12.64M	13.26M	16.26M	19.46M	27.31M	38.50M	43.21M	45.30M	47M

This table shows BioLife Solutions' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-10	-49	-14	-10	-29	-15	-10	-21	-1.70	12
Consolidated Net Income / (Loss)	-10	-49	-14	-10	-29	-15	-10	-21	-1.70	12
Net Income / (Loss) Continuing Operations	-10	91	-14	-5.52	-16	17	-10	-7.15	-1.70	7.68
Total Pre-Tax Income	-11	91	-14	-5.52	-16	16	-10	-7.15	-1.73	7.54
Total Operating Income	-12	90	-14	-11	-15	16	-10	-2.80	-1.56	7.35
Total Gross Profit	14	7.06	14	11	12	8.88	13	15	16	9.92
Total Revenue	41	-41	38	29	24	-15	32	28	31	-8.37
Operating Revenue	41	-41	38	29	24	-15	32	28	31	-8.37
Total Cost of Revenue	27	-48	24	18	12	-24	19	13	14	-18
Operating Cost of Revenue	27	-48	24	18	12	-24	19	13	14	-18
Total Operating Expenses	25	-83	28	22	27	-7.39	23	18	18	2.57
Selling, General & Admin Expense	12	-1.84	15	14	11	4.07	13	11	11	5.36
Marketing Expense	5.28	-3.91	6.47	3.83	4.88	-2.47	5.07	3.50	3.54	-2.51
Research & Development Expense	3.43	-1.96	4.15	3.79	3.74	0.39	3.53	2.38	2.05	-0.05
Amortization Expense	2.51	-4.25	1.46	1.41	1.31	-0.66	0.91	0.91	0.91	0.00
Total Other Income / (Expense), net	0.82	0.36	-0.02	5.11	-0.21	0.09	0.04	-4.35	-0.17	0.19
Interest & Investment Income	0.68	-	-0.41	-0.39	-0.45	-0.20	-0.21	-4.44	-0.27	0.12
Other Income / (Expense), net	0.14	0.41	0.39	5.50	0.24	0.29	0.25	0.08	0.10	0.07
Income Tax Expense	-0.60	-0.30	0.09	0.00	0.12	-0.23	0.13	0.00	-0.03	-0.14
Basic Earnings per Share	($0.24)	($1.15)	($0.32)	($0.23)	($0.67)	($0.33)	($0.22)	($0.45)	($0.04)	$0.27
Weighted Average Basic Shares Outstanding	42.65M	42.48M	43.03M	43.44M	14.44M	43.72M	45.43M	25.29M	46.18M	46.07M
Diluted Earnings per Share	($0.24)	-	($0.32)	($0.23)	($0.67)	($0.33)	($0.22)	($0.45)	($0.04)	$0.27
Weighted Average Diluted Shares Outstanding	42.65M	43.07M	43.03M	43.44M	43.57M	43.72M	45.43M	46.00M	46.18M	46.07M
Weighted Average Basic & Diluted Shares Outstanding	42.77M	43.21M	43.46M	43.49M	44.03M	45.30M	46.03M	46.14M	46.39M	47M

This table details how cash moves in and out of BioLife Solutions' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	2.38	-0.37	-0.77	5.26	24	-15	84	-21	-50	16	60
Net Cash From Operating Activities	-3.16	-4.97	-4.33	0.61	2.35	1.21	6.65	-4.59	-8.49	-12	8.43
Net Cash From Continuing Operating Activities	-3.16	-4.97	-4.33	0.61	2.35	11	6.65	-4.59	-8.49	-12	8.43
Net Income / (Loss) Continuing Operations	-3.30	-5.00	-8.04	-2.52	-25	-1.66	1.98	-8.91	-140	-68	-20
Consolidated Net Income / (Loss)	-3.30	-5.00	-8.04	-2.52	-25	-1.66	1.98	-8.91	-140	-68	-20
Depreciation Expense	0.26	0.34	0.37	0.34	0.34	0.72	2.04	4.66	6.78	7.11	5.16
Amortization Expense	0.07	-0.04	0.09	0.03	0.00	1.08	3.03	8.32	9.27	3.93	3.03
Non-Cash Adjustments To Reconcile Net Income	0.65	0.55	3.81	2.45	30	16	2.17	19	140	45	20
Changes in Operating Assets and Liabilities, net	-0.85	-0.83	-0.56	0.30	-3.22	-5.24	-2.58	-28	-25	-0.79	0.16
Net Cash From Investing Activities	-8.14	4.24	0.39	-0.14	-6.50	-27	-25	-13	-58	18	58
Net Cash From Continuing Investing Activities	-8.14	4.24	0.39	-0.14	-6.50	-27	-25	-13	-58	18	58
Purchase of Property, Plant & Equipment	-0.59	-1.42	-1.26	-0.14	-0.50	-0.68	-1.96	-8.39	-10	-6.38	-3.23
Acquisitions	-	-	-	-	-6.00	-23	-15	-	0.00	0.00	-0.30
Purchase of Investments	-7.95	-1.41	-	0.00	0.00	-1.00	0.00	0.00	-53	-27	-18
Divestitures	-	-	-	-	-	1.25	0.00	1.56	0.00	0.00	73
Sale and/or Maturity of Investments	0.40	7.07	1.65	-	-	-	0.00	0.00	8.92	56	22
Other Investing Activities, net	-	-	-	-	0.00	-3.16	-7.84	-6.37	-3.54	-4.86	-15
Net Cash From Financing Activities	14	0.37	3.17	4.80	28	1.60	102	-2.78	16	11	-6.78
Net Cash From Continuing Financing Activities	14	0.37	3.17	4.80	28	1.60	96	-2.78	16	11	-6.78
Repayment of Debt	-	0.00	0.00	-0.01	-0.07	-0.16	-2.23	-32	-2.50	-0.43	-6.68
Repurchase of Common Equity	-	0.00	-0.11	-0.05	-	0.00	-6.20	-0.15	-0.13	0.00	0.00
Issuance of Debt	-	-	3.00	1.00	-	0.00	3.16	29	20	0.00	0.00
Issuance of Common Equity	14	-	-	0.00	20	0.00	100	0.00	0.00	10	0.00
Other Financing Activities, net	0.08	0.37	0.28	3.97	13	1.76	1.03	0.39	-1.05	0.78	-0.10
Other Net Changes in Cash	-	-	-	-	-	-	-	-	-0.11	0.04	0.00
Cash Interest Paid	-	-	-	-	-	0.00	0.00	0.45	0.59	1.93	1.61

This table details how cash moves in and out of BioLife Solutions' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	3.02	-7.66	-0.35	2.28	-2.11	16	-5.65	-7.68	2.08	71
Net Cash From Operating Activities	1.50	7.86	-2.71	-7.72	-4.38	2.31	-4.48	6.46	4.80	1.65
Net Cash From Continuing Operating Activities	1.50	7.86	-2.71	-7.72	-4.38	2.31	-4.48	6.46	4.80	1.65
Net Income / (Loss) Continuing Operations	-10	-49	-14	-10	-29	-15	-10	-21	-1.70	12
Consolidated Net Income / (Loss)	-10	-49	-14	-10	-29	-15	-10	-21	-1.70	12
Depreciation Expense	1.80	1.72	1.72	2.00	1.92	1.47	1.36	1.45	1.41	0.94
Amortization Expense	2.51	1.03	1.08	1.10	1.05	0.70	0.73	0.77	0.82	0.70
Non-Cash Adjustments To Reconcile Net Income	7.22	54	8.73	-0.10	25	11	8.62	22	4.46	-15
Changes in Operating Assets and Liabilities, net	0.29	0.77	-0.53	-0.52	-3.42	3.68	-4.97	3.13	-0.18	2.18
Net Cash From Investing Activities	-16	-15	2.93	9.29	1.66	3.96	-0.22	-13	-1.68	74
Net Cash From Continuing Investing Activities	-16	-15	2.93	9.29	1.66	3.96	-0.22	-13	-1.68	74
Purchase of Property, Plant & Equipment	-2.45	-4.45	-3.30	-0.61	-1.50	-0.98	-0.36	-1.00	-1.11	-0.76
Purchase of Investments	-13	-17	-8.20	-7.53	-6.96	-4.41	-6.37	-4.34	-5.30	-2.40
Sale and/or Maturity of Investments	0.75	8.17	15	19	11	11	6.97	6.07	5.17	3.71
Other Investing Activities, net	-1.50	-1.27	-1.00	-1.55	-0.90	-1.40	-0.46	-14	-0.43	-0.04
Net Cash From Financing Activities	17	-0.63	-0.56	0.70	0.61	9.84	-0.95	-0.70	-1.04	-4.09
Net Cash From Continuing Financing Activities	17	-0.63	-0.56	0.70	0.61	9.84	-0.95	-0.70	-1.04	-4.09
Repayment of Debt	-2.19	-0.08	-0.12	-0.15	-0.33	0.17	-0.23	-0.28	-2.70	-3.48
Other Financing Activities, net	-0.27	-0.55	-0.44	0.86	0.94	-0.58	-0.73	-0.43	1.66	-0.60
Cash Interest Paid	0.11	0.36	0.50	0.44	0.46	0.53	0.45	0.38	0.41	0.37

This table presents BioLife Solutions' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	16	12	7.93	12	45	93	235	554	450	413	399
Total Current Assets	12	6.97	4.63	9.93	38	24	115	126	138	121	149
Cash & Equivalents	2.54	2.17	1.41	6.66	31	6.45	90	70	19	28	95
Short-Term Investments	7.40	1.65	-	-	-	-	-	0.00	43	16	9.20
Accounts Receivable	0.90	0.93	1.19	1.02	3.05	5.35	8.01	23	34	7.90	9.17
Inventories, net	0.97	1.83	1.76	1.85	3.51	11	12	28	35	27	29
Prepaid Expenses	0.36	0.38	0.27	0.40	0.35	1.35	4.65	4.66	6.88	4.67	6.00
Other Current Nonoperating Assets	-	-	-	-	-	-	-	-	-	37	0.00
Plant, Property, & Equipment, net	1.66	1.45	1.19	1.11	1.32	5.57	10	18	24	5.69	6.08
Total Noncurrent Assets	2.25	3.95	2.11	1.11	6.58	63	110	411	288	286	245
Long-Term Investments	-	-	-	1.07	6.55	2.50	5.87	4.37	6.40	5.62	5.62
Goodwill	-	-	-	-	0.00	34	58	225	225	212	212
Intangible Assets	2.22	2.22	-	-	0.00	22	31	152	32	12	9.56
Other Noncurrent Operating Assets	0.04	1.73	2.11	0.04	0.04	5.01	15	29	25	14	17
Other Noncurrent Nonoperating Assets	-	-	-	-	-	-	-	-	-	43	0.00
Total Liabilities & Shareholders' Equity	16	12	7.93	12	45	93	235	554	450	413	399
Total Liabilities	2.14	2.51	4.76	2.05	31	49	30	76	86	75	51
Total Current Liabilities	1.26	1.73	1.13	1.51	1.94	7.67	16	43	45	42	33
Short-Term Debt	-	-	-	-	0.00	0.38	3.25	5.99	3.95	6.29	11
Accounts Payable	0.47	1.03	0.71	0.69	0.72	3.12	3.67	15	15	2.27	3.57
Accrued Expenses	0.12	0.15	0.12	0.20	1.22	3.37	4.76	16	18	9.12	12
Current Deferred & Payable Income Tax Liabilities	-	-	-	-	-	-	-	2.59	4.15	4.40	4.26
Other Current Liabilities	0.13	-	-	-	0.00	0.80	3.90	2.91	3.02	1.29	1.51
Other Current Nonoperating Liabilities	-	-	-	-	-	-	-	-	-	19	0.00
Total Noncurrent Liabilities	0.87	0.78	3.63	0.54	29	42	14	34	41	33	18
Long-Term Debt	-	-	2.84	-	-	-	0.66	6.35	24	18	5.00
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	-	-	-	-	0.00	5.49	0.25	0.11	0.12
Other Noncurrent Operating Liabilities	-	0.00	0.10	0.05	29	42	13	21	17	8.70	13
Other Noncurrent Nonoperating Liabilities	-	-	-	-	-	-	-	-	-	6.50	0.00
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	14	9.86	3.17	10	15	43	205	478	364	338	349
Total Preferred & Common Equity	12	8.51	3.17	10	15	43	205	478	364	338	349
Preferred Stock	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	12	8.51	3.17	10	15	43	205	478	364	338	349
Common Stock	72	73	74	84	113	144	303	585	612	653	684
Retained Earnings	-60	-64	-71	-74	-98	-100	-97	-107	-247	-315	-335
Accumulated Other Comprehensive Income / (Loss)	-	-	-	-	-	-	0.00	-0.28	-0.68	-0.35	0.02

This table presents BioLife Solutions' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	488	446	433	411	402	375	382
Total Current Assets	136	133	120	117	112	88	89
Cash & Equivalents	27	19	21	19	30	22	24
Restricted Cash	0.03	0.03	0.03	0.03	0.03	0.03	0.18
Short-Term Investments	35	36	25	22	16	12	10
Accounts Receivable	32	30	27	25	19	18	18
Inventories, net	34	41	39	43	43	32	32
Prepaid Expenses	8.04	6.20	7.99	7.85	4.41	3.48	4.91
Other Current Nonoperating Assets	-	-	-	-	-	0.00	0.00
Plant, Property, & Equipment, net	22	26	26	21	21	17	18
Total Noncurrent Assets	330	288	287	273	269	270	275
Long-Term Investments	5.07	7.09	6.91	6.23	5.07	3.68	5.88
Noncurrent Note & Lease Receivables	0.31	0.24	1.81	0.12	0.07	0.04	0.03
Goodwill	225	225	225	225	225	225	225
Intangible Assets	74	31	29	22	20	19	18
Other Noncurrent Operating Assets	25	25	25	20	19	22	25
Other Noncurrent Nonoperating Assets	-	-	-	-	-	0.00	0.00
Total Liabilities & Shareholders' Equity	488	446	433	411	402	375	382
Total Liabilities	79	88	81	79	68	54	56
Total Current Liabilities	37	47	40	43	39	31	32
Short-Term Debt	4.74	4.55	2.02	5.09	8.62	11	12
Accounts Payable	13	16	11	12	4.98	4.21	3.84
Accrued Expenses	16	20	19	17	17	8.31	8.64
Current Deferred & Payable Income Tax Liabilities	-	4.59	4.99	5.47	5.40	4.86	4.35
Other Current Liabilities	2.93	3.07	3.34	3.30	3.00	2.82	3.11
Other Current Nonoperating Liabilities	-	-	-	-	-	0.00	0.00
Total Noncurrent Liabilities	42	41	41	37	30	23	24
Long-Term Debt	24	24	24	21	16	10	7.82
Capital Lease Obligations	0.17	0.10	1.33	1.25	1.09	1.00	0.91
Noncurrent Deferred & Payable Income Tax Liabilities	0.39	0.26	0.26	0.29	0.19	0.19	0.10
Other Noncurrent Operating Liabilities	18	17	16	14	13	11	15
Other Noncurrent Nonoperating Liabilities	-	-	-	-	-	0.00	0.00
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	408	358	352	332	333	321	325
Total Preferred & Common Equity	408	358	352	332	333	321	325
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	408	358	352	332	333	321	325
Common Stock	604	619	623	633	659	668	673
Retained Earnings	-195	-261	-271	-300	-325	-346	-348
Accumulated Other Comprehensive Income / (Loss)	-1.26	-0.53	-0.50	-0.66	-0.57	-0.56	-0.21

This table displays calculated financial ratios and metrics derived from BioLife Solutions' official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-30.83%	4.17%	27.57%	33.97%	79.11%	38.64%	75.69%	147.79%	-36.02%	-0.50%	8.44%
EBITDA Growth	-20,219.94%	-67.94%	6.40%	81.86%	-2,949.12%	159.33%	-83.14%	-1,006.34%	149.00%	-155.43%	126.02%
EBIT Growth	-813.46%	-59.93%	2.90%	76.00%	-2,014.18%	151.21%	-120.95%	-1,225.45%	84.97%	-223.55%	61.04%
NOPAT Growth	-998.87%	-60.00%	3.30%	78.23%	446.78%	-106.01%	-2,736.82%	-463.37%	83.15%	-295.75%	69.59%
Net Income Growth	-204.46%	-51.34%	-60.98%	68.72%	-894.23%	93.37%	219.67%	-549.22%	-1,469.43%	51.36%	70.32%
EPS Growth	-40.91%	-12.90%	-54.29%	61.11%	-642.86%	94.23%	33.33%	-283.33%	-1,313.04%	52.31%	71.61%
Operating Cash Flow Growth	-2,265.87%	-57.29%	13.01%	113.98%	288.10%	-48.34%	447.82%	-169.12%	-84.80%	-47.24%	167.46%
Free Cash Flow Firm Growth	-1,752.95%	38.47%	64.58%	176.62%	1,725.58%	-309.53%	-42.89%	-298.70%	127.23%	-45.37%	-103.96%
Invested Capital Growth	241.54%	50.95%	-23.70%	-48.77%	-1,056.89%	254.53%	223.47%	269.06%	-22.46%	-20.20%	-1.19%
Revenue Q/Q Growth	-9.08%	2.37%	5.52%	8.73%	13.33%	11.58%	15.44%	23.38%	-50.75%	-43.72%	-42.63%
EBITDA Q/Q Growth	-17.70%	-16.36%	16.42%	19.63%	-1,029.67%	135.34%	-93.09%	-66.71%	111.20%	91.56%	104.30%
EBIT Q/Q Growth	-28.06%	-9.12%	13.76%	20.53%	-1,119.70%	130.17%	-108.61%	-51.55%	95.39%	79.34%	85.24%
NOPAT Q/Q Growth	-29.78%	-8.66%	13.80%	27.92%	6.74%	-113.90%	-119.91%	-59.07%	94.84%	73.66%	84.37%
Net Income Q/Q Growth	-18.32%	-8.83%	-36.82%	54.46%	-1,477.52%	94.82%	-74.51%	-321.32%	-31.44%	33.48%	56.15%
EPS Q/Q Growth	-34.78%	-6.06%	-45.95%	48.78%	-4,000.00%	96.10%	66.67%	0.00%	0.00%	0.00%	56.44%
Operating Cash Flow Q/Q Growth	-32.48%	-13.03%	12.22%	169.86%	-8.49%	-56.69%	96.31%	-194.05%	50.42%	-79.78%	-7.32%
Free Cash Flow Firm Q/Q Growth	-58.91%	22.01%	63.73%	-5.87%	-46.39%	1.38%	-34.59%	9.78%	419.61%	1,279.40%	92.59%
Invested Capital Q/Q Growth	142.61%	9.11%	-34.31%	-46.19%	49.28%	132.20%	52.06%	-1.44%	-12.76%	-17.41%	-16.83%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	49.03%	59.15%	58.09%	61.20%	68.51%	68.00%	57.07%	31.09%	61.53%	60.55%	65.25%
EBITDA Margin	-45.10%	-72.71%	-53.35%	-7.22%	-122.94%	52.61%	5.05%	-18.47%	14.14%	-7.88%	1.89%
Operating Margin	-50.65%	-77.80%	-58.97%	-9.58%	18.55%	-0.80%	-12.98%	-29.51%	-7.77%	-30.90%	-8.67%
EBIT Margin	-50.45%	-77.46%	-58.96%	-10.56%	-124.65%	46.04%	-5.49%	-29.37%	-6.90%	-22.44%	-8.06%
Profit (Net Income) Margin	-53.32%	-77.46%	-97.74%	-22.82%	-126.66%	-6.05%	4.12%	-7.48%	-183.38%	-89.65%	-24.54%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	51.81%	-154.80%	30.69%	2,883.77%	368.16%	176.67%
Interest Burden Percent	105.68%	100.00%	165.79%	216.07%	101.61%	-25.38%	48.52%	82.95%	92.15%	108.51%	172.27%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-374.17%	-70.01%	-63.84%	-21.23%	0.00%	-2.50%	-5.91%	-9.30%	-1.12%	-5.65%	-1.95%
ROIC Less NNEP Spread (ROIC-NNEP)	-809.13%	-48.45%	325.47%	35.19%	0.00%	4.06%	-18.49%	-29.69%	262.62%	79.47%	15.49%
Return on Net Nonoperating Assets (RNNOA)	-618.86%	28.03%	-59.63%	-16.71%	0.00%	-3.20%	7.51%	6.69%	-32.08%	-13.73%	-3.93%
Return on Equity (ROE)	-993.02%	-41.99%	-123.47%	-37.94%	-202.27%	-5.71%	1.59%	-2.61%	-33.20%	-19.38%	-5.88%
Cash Return on Invested Capital (CROIC)	-225.56%	-110.62%	-36.95%	43.26%	0.00%	-165.15%	-111.46%	-124.02%	24.17%	16.82%	-0.76%
Operating Return on Assets (OROA)	-32.16%	-35.13%	-47.80%	-11.60%	-85.43%	18.23%	-1.61%	-8.87%	-1.05%	-3.95%	-1.63%
Return on Assets (ROA)	-33.98%	-35.13%	-79.24%	-25.06%	-86.81%	-2.40%	1.21%	-2.26%	-27.84%	-15.76%	-4.97%
Return on Common Equity (ROCE)	2,192.11%	-35.84%	-110.67%	-37.94%	-202.27%	-5.71%	1.59%	-2.61%	-33.20%	-19.38%	-5.88%
Return on Equity Simple (ROE_SIMPLE)	-27.96%	-58.71%	-253.98%	-24.92%	-170.89%	-3.81%	0.97%	-1.86%	-38.39%	-20.14%	-5.78%
Net Operating Profit after Tax (NOPAT)	-2.19	-3.51	-3.40	-0.74	2.56	-0.15	-4.37	-25	-4.15	-16	-4.99
NOPAT Margin	-35.46%	-54.46%	-41.28%	-6.71%	12.98%	-0.56%	-9.09%	-20.66%	-5.44%	-21.63%	-6.07%
Net Nonoperating Expense Percent (NNEP)	434.97%	-21.56%	-389.31%	-56.42%	-122.70%	-6.57%	12.58%	20.39%	-263.74%	-85.12%	-17.44%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-1.06%	-4.54%	-1.37%
Cost of Revenue to Revenue	50.97%	40.86%	41.91%	38.80%	31.49%	32.00%	42.93%	68.91%	38.47%	39.45%	34.75%
SG&A Expenses to Revenue	64.13%	75.50%	55.82%	41.04%	30.14%	32.49%	31.76%	28.26%	43.62%	57.04%	49.29%
R&D to Revenue	14.07%	21.38%	24.66%	10.82%	6.57%	11.57%	13.97%	9.92%	11.37%	15.92%	9.62%
Operating Expenses to Revenue	99.68%	136.94%	117.06%	70.79%	49.96%	68.80%	70.04%	60.60%	69.30%	91.45%	73.92%
Earnings before Interest and Taxes (EBIT)	-3.12	-5.00	-4.85	-1.16	-25	13	-2.64	-35	-5.26	-17	-6.63
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-2.79	-4.69	-4.39	-0.80	-24	14	2.43	-22	11	-5.98	1.56
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.68	3.12	6.55	8.10	15.21	7.62	6.36	3.25	2.14	2.12	3.45
Price to Tangible Book Value (P/TBV)	2.07	4.22	6.55	8.10	15.21	0.00	11.28	15.34	7.25	6.31	9.48
Price to Revenue (P/Rev)	3.20	4.12	2.52	7.42	11.27	12.09	27.16	13.03	10.21	9.43	14.64
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	658.52	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.15%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	3.00	3.99	4.82	31.39	0.00	9.24	10.75	3.58	2.28	2.68	4.36
Enterprise Value to Revenue (EV/Rev)	1.94	3.74	2.70	6.72	9.39	11.78	25.23	12.51	9.67	9.09	13.49
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	22.39	499.76	0.00	68.36	0.00	713.79
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	25.58	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	72.31	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	122.40	78.94	265.74	182.61	0.00	0.00	0.00	131.65
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	49.17	6.74	0.00	0.00	0.00	8.25	14.12	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.90	0.00	0.00	0.01	0.02	0.03	0.08	0.07	0.05
Long-Term Debt to Equity	0.00	0.00	0.90	0.00	0.00	0.00	0.00	0.01	0.07	0.05	0.01
Financial Leverage	0.76	-0.58	-0.18	-0.47	-1.82	-0.79	-0.41	-0.23	-0.12	-0.17	-0.25
Leverage Ratio	29.22	1.20	1.56	1.51	2.33	2.38	1.32	1.15	1.19	1.23	1.18
Compound Leverage Factor	30.88	1.20	2.58	3.27	2.37	-0.60	0.64	0.96	1.10	1.33	2.04
Debt to Total Capital	0.00%	0.00%	47.32%	0.00%	0.00%	0.86%	1.87%	2.57%	7.11%	6.60%	4.37%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.86%	1.55%	1.22%	1.01%	1.74%	3.00%
Long-Term Debt to Total Capital	0.00%	0.00%	47.32%	0.00%	0.00%	0.00%	0.32%	1.35%	6.10%	4.86%	1.37%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	15.30%	13.70%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	84.70%	86.30%	52.68%	100.00%	100.00%	99.14%	98.13%	97.43%	92.89%	93.40%	95.63%
Debt to EBITDA	0.00	0.00	-0.65	0.00	0.00	0.03	1.61	-0.57	2.59	-3.99	10.25
Net Debt to EBITDA	0.00	0.00	-0.33	0.00	0.00	-0.60	-38.06	2.80	-3.83	4.34	-60.62
Long-Term Debt to EBITDA	0.00	0.00	-0.65	0.00	0.00	0.00	0.27	-0.30	2.22	-2.94	3.21
Debt to NOPAT	0.00	0.00	-0.84	0.00	0.00	-2.45	-0.90	-0.51	-6.72	-1.45	-3.19
Net Debt to NOPAT	0.00	0.00	-0.42	0.00	0.00	55.66	21.15	2.50	9.95	1.58	18.89
Long-Term Debt to NOPAT	0.00	0.00	-0.84	0.00	0.00	0.00	-0.15	-0.27	-5.77	-1.07	-1.00
Altman Z-Score	0.89	-1.23	-10.41	16.82	0.89	3.47	26.58	12.13	5.04	4.93	13.61
Noncontrolling Interest Sharing Ratio	320.75%	14.64%	10.37%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	9.64	4.04	4.08	6.56	19.37	3.14	7.37	2.95	3.11	2.86	4.54
Quick Ratio	8.59	2.75	2.29	5.08	17.38	1.54	6.32	2.18	2.17	1.23	3.48
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-9.02	-5.55	-1.97	1.51	27	-58	-82	-328	89	49	-1.93
Operating Cash Flow to CapEx	-540.31%	-350.84%	-344.17%	420.14%	469.60%	179.70%	345.02%	-54.81%	-81.73%	-195.86%	261.26%
Free Cash Flow to Firm to Interest Expense	-50.86	0.00	-4.85	4.35	5,499.08	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-17.84	0.00	-10.68	1.75	469.60	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-21.14	0.00	-13.78	1.33	369.60	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.64	0.45	0.81	1.10	0.69	0.40	0.29	0.30	0.15	0.18	0.20
Accounts Receivable Turnover	6.48	7.04	7.75	9.95	9.71	6.52	7.20	7.63	2.67	3.63	9.64
Inventory Turnover	4.55	1.88	1.92	2.37	2.32	1.21	1.83	4.11	0.93	0.96	1.02
Fixed Asset Turnover	4.16	4.16	6.25	9.61	16.28	7.94	6.13	8.58	3.69	5.17	13.97
Accounts Payable Turnover	4.70	3.50	3.96	6.10	8.81	4.56	6.08	8.82	1.94	3.39	9.78
Days Sales Outstanding (DSO)	56.33	51.81	47.09	36.67	37.59	55.94	50.67	47.82	136.81	100.65	37.87
Days Inventory Outstanding (DIO)	80.17	193.94	190.13	153.85	157.23	301.69	199.54	88.79	393.58	378.56	358.69
Days Payable Outstanding (DPO)	77.61	104.18	92.09	59.83	41.42	79.98	60.03	41.38	188.62	107.57	37.31
Cash Conversion Cycle (CCC)	58.90	141.57	145.13	130.70	153.39	277.65	190.18	95.23	341.77	371.64	359.24
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	4.00	6.03	4.60	2.36	-23	35	113	416	323	258	255
Invested Capital Turnover	10.55	1.29	1.55	3.17	-1.95	4.45	0.65	0.45	0.21	0.26	0.32
Increase / (Decrease) in Invested Capital	6.82	2.04	-1.43	-2.25	-25	57	78	304	-94	-65	-3.06
Enterprise Value (EV)	12	24	22	74	185	322	1,213	1,491	737	690	1,110
Market Capitalization	20	27	21	82	223	331	1,306	1,552	778	716	1,204
Book Value per Share	$0.98	$0.69	$0.25	$0.74	$0.79	$2.12	$6.27	$11.48	$8.52	$7.67	$7.52
Tangible Book Value per Share	$0.79	$0.51	$0.25	$0.74	$0.79	($0.59)	$3.54	$2.43	$2.51	$2.57	$2.74
Total Capital	14	9.86	6.01	10	15	44	209	491	392	362	365
Total Debt	0.00	0.00	2.84	0.00	0.00	0.38	3.92	13	28	24	16
Total Long-Term Debt	0.00	0.00	2.84	0.00	0.00	0.00	0.67	6.64	24	18	5.00
Net Debt	-9.94	-3.82	1.44	-7.73	-37	-8.57	-92	-62	-41	-26	-94
Capital Expenditures (CapEx)	0.59	1.42	1.26	0.14	0.50	0.68	1.93	8.38	10	6.38	3.23
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.97	1.42	2.09	1.76	4.97	10	12	20	35	41	22
Debt-free Net Working Capital (DFNWC)	11	5.25	3.49	8.42	36	17	102	89	98	85	127
Net Working Capital (NWC)	11	5.25	3.49	8.42	36	16	99	83	94	78	116
Net Nonoperating Expense (NNE)	1.11	1.48	4.65	1.78	28	1.50	-6.35	-16	136	52	15
Net Nonoperating Obligations (NNO)	-9.94	-3.82	1.44	-7.73	-37	-8.57	-92	-62	-41	-80	-94
Total Depreciation and Amortization (D&A)	0.33	0.31	0.46	0.37	0.34	1.80	5.07	13	16	11	8.19
Debt-free, Cash-free Net Working Capital to Revenue	15.60%	22.06%	25.39%	15.92%	25.16%	37.90%	24.82%	16.37%	46.03%	53.43%	27.22%
Debt-free Net Working Capital to Revenue	176.14%	81.36%	42.48%	76.37%	180.45%	61.46%	212.93%	75.01%	128.31%	111.67%	154.36%
Net Working Capital to Revenue	176.14%	81.36%	42.48%	76.37%	180.45%	60.08%	206.17%	69.98%	123.13%	103.39%	141.06%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.31)	($0.35)	($0.54)	($0.21)	$0.18	($0.09)	$0.09	($0.20)	($3.29)	($1.52)	($0.44)
Adjusted Weighted Average Basic Shares Outstanding	12.10M	12.45M	13.00M	14.12M	16.26M	19.46M	33.40M	42.09M	42.48M	43.72M	46.07M
Adjusted Diluted Earnings per Share	($0.31)	($0.35)	($0.54)	($0.21)	$0.14	($0.09)	($0.03)	($0.20)	($3.29)	($1.52)	($0.44)
Adjusted Weighted Average Diluted Shares Outstanding	12.10M	12.45M	13.00M	14.12M	21.63M	19.46M	33.40M	42.09M	43.21M	43.72M	46.07M
Adjusted Basic & Diluted Earnings per Share	($0.31)	($0.35)	($0.54)	($0.21)	$0.00	($0.09)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	10.45M	12.18M	12.64M	13.26M	18.65M	19.46M	27.31M	38.50M	43.21M	45.30M	47M
Normalized Net Operating Profit after Tax (NOPAT)	-2.19	-3.51	-3.40	-0.74	2.56	0.54	-2.80	-21	-7.47	-18	-4.99
Normalized NOPAT Margin	-35.46%	-54.46%	-41.28%	-6.71%	12.98%	1.97%	-5.82%	-18.01%	-9.80%	-23.65%	-6.07%
Pre Tax Income Margin	-53.32%	-77.46%	-97.74%	-22.82%	-126.66%	-11.68%	-2.66%	-24.36%	-6.36%	-24.35%	-13.89%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-17.62	0.00	-11.97	-3.36	-4,921.80	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-12.38	0.00	-8.38	-2.14	512.68	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-20.92	0.00	-15.08	-3.78	-5,021.80	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-15.68	0.00	-11.49	-2.55	412.68	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	-4.21%	-1.74%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	-1.39%	-6.28%	-1.74%	0.00%	312.66%	-1.63%	-0.09%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from BioLife Solutions' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	20.55%	-210.60%	4.09%	-27.87%	-42.15%	64.47%	-15.85%	-3.11%	29.69%	42.88%
EBITDA Growth	2.84%	789.70%	-213.49%	97.19%	-68.39%	-79.97%	25.18%	76.04%	106.23%	-51.61%
EBIT Growth	-3.87%	599.52%	-68.59%	93.30%	-31.40%	-81.76%	25.19%	47.14%	90.39%	-55.15%
NOPAT Growth	-5.21%	801.29%	-70.77%	86.12%	-31.81%	-81.80%	25.56%	73.70%	89.93%	-54.60%
Net Income Growth	-13,159.49%	-212.41%	-84.80%	86.01%	-182.37%	69.59%	25.47%	-103.15%	94.15%	183.30%
EPS Growth	0.00%	0.00%	0.00%	86.63%	-179.17%	0.00%	31.25%	-95.65%	94.03%	181.82%
Operating Cash Flow Growth	-28.18%	1,115.12%	65.77%	22.17%	-392.71%	-70.59%	-65.01%	183.69%	209.66%	-28.82%
Free Cash Flow Firm Growth	112.39%	158.18%	129.07%	193.41%	7.20%	-55.62%	-90.24%	-50.63%	-89.99%	-87.10%
Invested Capital Growth	-12.39%	-22.46%	-23.75%	-11.99%	-15.71%	-20.20%	-4.94%	-6.20%	-1.87%	-1.19%
Revenue Q/Q Growth	0.53%	-201.26%	-14.81%	-22.45%	-19.37%	-162.18%	-26.22%	-10.71%	7.92%	-127.39%
EBITDA Q/Q Growth	89.89%	1,383.05%	77.41%	80.55%	-506.32%	252.61%	49.42%	93.77%	257.53%	1,086.26%
EBIT Q/Q Growth	84.86%	882.53%	72.94%	61.18%	-197.13%	208.65%	43.73%	72.57%	46.00%	607.24%
NOPAT Q/Q Growth	84.67%	1,203.00%	72.39%	21.88%	-45.61%	252.32%	43.13%	72.40%	44.22%	786.38%
Net Income Q/Q Growth	85.84%	-376.78%	72.12%	25.63%	-185.64%	48.66%	23.62%	-102.71%	91.78%	831.59%
EPS Q/Q Growth	86.05%	0.00%	0.00%	28.13%	-191.30%	50.75%	26.67%	-104.55%	91.11%	775.00%
Operating Cash Flow Q/Q Growth	115.09%	425.20%	-134.52%	-184.59%	43.26%	152.77%	-293.64%	244.34%	-25.65%	-65.74%
Free Cash Flow Firm Q/Q Growth	211.57%	317.26%	55.06%	-59.63%	28.05%	72.73%	159.34%	104.32%	-74.03%	122.65%
Invested Capital Q/Q Growth	-0.03%	-12.76%	0.47%	0.44%	-4.25%	-17.41%	0.46%	-0.90%	0.17%	-16.83%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	33.72%	0.00%	37.24%	37.71%	50.88%	0.00%	39.59%	52.57%	53.30%	0.00%
EBITDA Margin	-17.89%	0.00%	-27.61%	-6.92%	-52.06%	0.00%	-24.54%	-1.71%	2.50%	0.00%
Operating Margin	-28.81%	0.00%	-36.08%	-36.35%	-65.65%	0.00%	-31.92%	-9.87%	-5.10%	0.00%
EBIT Margin	-28.46%	0.00%	-35.04%	-17.54%	-64.65%	0.00%	-31.15%	-9.57%	-4.79%	0.00%
Profit (Net Income) Margin	-25.32%	0.00%	-36.37%	-34.88%	-123.58%	0.00%	-32.22%	-73.14%	-5.57%	0.00%
Tax Burden Percent	94.51%	-54.23%	100.68%	184.90%	185.68%	-91.45%	101.30%	289.94%	98.38%	165.19%
Interest Burden Percent	94.12%	99.94%	103.11%	107.55%	102.95%	98.78%	102.09%	263.59%	118.24%	101.56%
Effective Tax Rate	0.00%	-0.33%	0.00%	0.00%	0.00%	-1.42%	0.00%	0.00%	0.00%	-1.87%
Return on Invested Capital (ROIC)	-7.88%	0.00%	-11.00%	-11.11%	-18.16%	0.00%	-9.70%	-2.98%	-1.66%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-3.87%	0.00%	-1.33%	-3.03%	44.82%	0.00%	0.98%	86.23%	1.46%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.45%	0.00%	0.14%	0.27%	-3.52%	0.00%	-0.08%	-5.38%	-0.09%	0.00%
Return on Equity (ROE)	-7.43%	0.00%	-10.86%	-10.84%	-21.68%	0.00%	-9.78%	-8.37%	-1.74%	0.00%
Cash Return on Invested Capital (CROIC)	-7.06%	24.17%	-1.27%	-4.39%	-1.21%	16.82%	-9.84%	-6.80%	-8.44%	-0.76%
Operating Return on Assets (OROA)	-8.42%	0.00%	-11.55%	-5.90%	-19.39%	0.00%	-10.09%	-3.23%	-1.73%	0.00%
Return on Assets (ROA)	-7.49%	0.00%	-11.99%	-11.73%	-37.06%	0.00%	-10.43%	-24.69%	-2.02%	0.00%
Return on Common Equity (ROCE)	-7.43%	0.00%	-10.86%	-10.84%	-21.68%	0.00%	-9.78%	-8.37%	-1.74%	0.00%
Return on Equity Simple (ROE_SIMPLE)	-26.05%	0.00%	-40.80%	-23.69%	-30.79%	0.00%	-18.88%	-22.85%	-14.14%	0.00%
Net Operating Profit after Tax (NOPAT)	-8.22	91	-9.52	-7.44	-11	16	-7.09	-1.96	-1.09	7.49
NOPAT Margin	-20.17%	0.00%	-25.26%	-25.45%	-45.95%	0.00%	-22.35%	-6.91%	-3.57%	0.00%
Net Nonoperating Expense Percent (NNEP)	-4.00%	-271.86%	-9.67%	-8.08%	-62.98%	-51.90%	-10.68%	-89.22%	-3.11%	5.70%
Return On Investment Capital (ROIC_SIMPLE)	-	23.12%	-	-	-	4.56%	-	-	-	2.05%
Cost of Revenue to Revenue	66.28%	0.00%	62.76%	62.29%	49.12%	0.00%	60.41%	47.43%	46.70%	0.00%
SG&A Expenses to Revenue	29.24%	0.00%	39.37%	46.31%	45.87%	0.00%	40.77%	38.46%	37.13%	0.00%
R&D to Revenue	8.41%	0.00%	11.01%	12.97%	15.86%	0.00%	11.14%	8.41%	6.71%	0.00%
Operating Expenses to Revenue	62.53%	0.00%	73.32%	74.06%	116.53%	0.00%	71.51%	62.44%	58.40%	0.00%
Earnings before Interest and Taxes (EBIT)	-12	91	-13	-5.13	-15	17	-9.88	-2.71	-1.46	7.43
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-7.29	94	-10	-2.02	-12	19	-7.79	-0.49	0.76	9.06
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.37	2.14	2.62	2.73	1.81	2.12	2.52	3.07	3.55	3.45
Price to Tangible Book Value (P/TBV)	8.85	7.25	9.15	9.78	7.05	6.31	9.50	12.75	14.04	9.48
Price to Revenue (P/Rev)	6.26	10.21	5.76	6.32	4.46	9.43	6.12	7.23	8.06	14.64
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.52	2.28	2.79	2.87	1.86	2.68	2.64	3.18	3.71	4.36
Enterprise Value to Revenue (EV/Rev)	6.02	9.67	5.55	6.15	4.31	9.09	5.94	7.12	7.92	13.49
Enterprise Value to EBITDA (EV/EBITDA)	0.00	68.36	0.00	0.00	0.00	0.00	0.00	0.00	0.00	713.79
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	124.88	131.65
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	8.25	0.00	0.00	0.00	14.12	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.07	0.08	0.08	0.08	0.08	0.07	0.08	0.07	0.06	0.05
Long-Term Debt to Equity	0.06	0.07	0.07	0.07	0.07	0.05	0.05	0.04	0.03	0.01
Financial Leverage	-0.12	-0.12	-0.10	-0.09	-0.08	-0.17	-0.08	-0.06	-0.06	-0.25
Leverage Ratio	1.17	1.19	1.18	1.18	1.21	1.23	1.23	1.20	1.21	1.18
Compound Leverage Factor	1.10	1.19	1.22	1.27	1.25	1.21	1.25	3.16	1.43	1.20
Debt to Total Capital	6.66%	7.11%	7.33%	7.10%	7.59%	6.60%	7.08%	6.42%	6.05%	4.37%
Short-Term Debt to Total Capital	1.08%	1.01%	1.18%	0.53%	1.42%	1.74%	2.40%	3.09%	3.53%	3.00%
Long-Term Debt to Total Capital	5.57%	6.10%	6.16%	6.57%	6.18%	4.86%	4.67%	3.33%	2.52%	1.37%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	93.34%	92.89%	92.67%	92.90%	92.41%	93.40%	92.92%	93.58%	93.95%	95.63%
Debt to EBITDA	-0.30	2.59	-0.21	-0.41	-0.39	-3.99	-0.50	-0.45	-0.58	10.25
Net Debt to EBITDA	0.39	-3.83	0.25	0.40	0.28	4.34	0.49	0.32	0.53	-60.62
Long-Term Debt to EBITDA	-0.25	2.22	-0.18	-0.38	-0.31	-2.94	-0.33	-0.23	-0.24	3.21
Debt to NOPAT	-0.36	-6.72	-0.27	-0.45	-0.44	-1.45	-0.54	-0.53	-0.66	-3.19
Net Debt to NOPAT	0.47	9.95	0.32	0.44	0.32	1.58	0.53	0.38	0.60	18.89
Long-Term Debt to NOPAT	-0.30	-5.77	-0.22	-0.42	-0.36	-1.07	-0.36	-0.27	-0.27	-1.00
Altman Z-Score	7.25	5.74	6.06	6.77	3.95	5.20	6.74	10.29	11.60	13.73
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.68	3.11	2.81	3.04	2.74	2.86	2.89	2.86	2.78	4.54
Quick Ratio	2.55	2.17	1.80	1.85	1.54	1.23	1.65	1.69	1.62	3.48
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	44	184	92	37	47	82	8.93	18	4.74	11
Operating Cash Flow to CapEx	61.16%	176.64%	-82.31%	-1,267.32%	-292.71%	235.58%	-1,257.02%	649.15%	431.06%	215.88%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.30	0.15	0.33	0.34	0.30	0.18	0.32	0.34	0.36	0.20
Accounts Receivable Turnover	5.88	2.67	5.98	5.23	4.73	3.63	5.61	6.07	6.75	9.64
Inventory Turnover	3.43	0.93	3.00	2.74	2.17	0.96	2.17	2.43	2.38	1.02
Fixed Asset Turnover	7.90	3.69	7.36	6.80	6.31	5.17	5.82	6.37	7.41	13.97
Accounts Payable Turnover	7.93	1.94	7.87	8.93	6.67	3.39	8.97	11.71	11.37	9.78
Days Sales Outstanding (DSO)	62.09	136.81	61.06	69.80	77.18	100.65	65.02	60.11	54.06	37.87
Days Inventory Outstanding (DIO)	106.43	393.58	121.82	133.44	168.03	378.56	168.07	149.93	153.26	358.69
Days Payable Outstanding (DPO)	46.03	188.62	46.39	40.89	54.74	107.57	40.67	31.17	32.10	37.31
Cash Conversion Cycle (CCC)	122.49	341.77	136.49	162.35	190.46	371.64	192.41	178.88	175.23	359.24
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	370	323	324	326	312	258	308	306	306	255
Invested Capital Turnover	0.39	0.21	0.44	0.44	0.40	0.26	0.43	0.43	0.46	0.32
Increase / (Decrease) in Invested Capital	-52	-94	-101	-44	-58	-65	-16	-20	-5.83	-3.06
Enterprise Value (EV)	932	737	906	934	581	690	815	971	1,136	1,110
Market Capitalization	969	778	940	960	601	716	840	986	1,155	1,204
Book Value per Share	$9.58	$8.52	$8.37	$8.10	$7.63	$7.67	$7.36	$6.98	$7.05	$7.52
Tangible Book Value per Share	$2.57	$2.51	$2.40	$2.26	$1.96	$2.57	$1.95	$1.68	$1.78	$2.74
Total Capital	437	392	386	379	359	362	359	344	346	365
Total Debt	29	28	28	27	27	24	25	22	21	16
Total Long-Term Debt	24	24	24	25	22	18	17	11	8.74	5.00
Net Debt	-38	-41	-34	-26	-20	-26	-25	-16	-19	-94
Capital Expenditures (CapEx)	2.45	4.45	3.30	0.61	1.50	0.98	0.36	1.00	1.11	0.76
Debt-free, Cash-free Net Working Capital (DFCFNWC)	42	35	35	36	38	41	36	34	35	22
Debt-free Net Working Capital (DFNWC)	104	98	90	83	79	85	82	68	69	127
Net Working Capital (NWC)	99	94	85	81	74	78	73	57	57	116
Net Nonoperating Expense (NNE)	2.10	140	4.19	2.76	18	31	3.13	19	0.61	-4.97
Net Nonoperating Obligations (NNO)	-38	-41	-34	-26	-20	-80	-25	-16	-19	-94
Total Depreciation and Amortization (D&A)	4.31	2.75	2.80	3.11	2.97	2.17	2.10	2.23	2.23	1.64
Debt-free, Cash-free Net Working Capital to Revenue	27.14%	46.03%	21.50%	23.99%	28.36%	53.43%	26.48%	24.80%	24.46%	27.22%
Debt-free Net Working Capital to Revenue	66.96%	128.31%	55.14%	54.46%	58.83%	111.67%	59.48%	49.85%	48.44%	154.36%
Net Working Capital to Revenue	63.90%	123.13%	52.36%	53.13%	55.06%	103.39%	53.20%	42.07%	39.90%	141.06%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.23)	($1.15)	($0.32)	($0.23)	($0.67)	($0.33)	($0.22)	($0.45)	($0.04)	$0.27
Adjusted Weighted Average Basic Shares Outstanding	42.65M	42.48M	43.03M	43.44M	43.57M	43.72M	45.43M	25.29M	46.18M	46.07M
Adjusted Diluted Earnings per Share	($0.23)	$0.00	$0.00	($0.23)	($0.67)	($0.33)	($0.22)	($0.45)	($0.04)	$0.27
Adjusted Weighted Average Diluted Shares Outstanding	42.65M	43.07M	43.46M	43.44M	43.57M	43.72M	45.43M	46.00M	46.18M	46.07M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	42.77M	43.21M	43.46M	43.49M	44.03M	45.30M	46.03M	46.14M	46.39M	47M
Normalized Net Operating Profit after Tax (NOPAT)	-6.58	62	-9.02	-8.08	-6.12	11	-6.92	-1.96	-1.09	5.15
Normalized NOPAT Margin	-16.14%	0.00%	-23.92%	-27.64%	-25.97%	0.00%	-21.82%	-6.91%	-3.57%	0.00%
Pre Tax Income Margin	-26.79%	0.00%	-36.13%	-18.87%	-66.56%	0.00%	-31.80%	-25.23%	-5.66%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.12%	-0.09%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About BioLife Solutions' Financials

When does BioLife Solutions's fiscal year end?

According to the most recent income statement we have on file, BioLife Solutions' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has BioLife Solutions' net income changed over the last 10 years?

BioLife Solutions' net income appears to be on an upward trend, with a most recent value of -$20.18 million in 2024, rising from -$3.30 million in 2014. The previous period was -$68.00 million in 2023.

What is BioLife Solutions's operating income?

BioLife Solutions's total operating income in 2024 was -$7.13 million, based on the following breakdown:

Total Gross Profit: $53.67 million
Total Operating Expenses: $60.80 million

How has BioLife Solutions revenue changed over the last 10 years?

Over the last 10 years, BioLife Solutions' total revenue changed from $6.19 million in 2014 to $82.25 million in 2024, a change of 1,228.7%.

How much debt does BioLife Solutions have?

BioLife Solutions' total liabilities were at $50.58 million at the end of 2024, a 32.6% decrease from 2023, and a 2,267.2% increase since 2014.

How much cash does BioLife Solutions have?

In the past 10 years, BioLife Solutions' cash and equivalents has ranged from $1.41 million in 2016 to $95.39 million in 2024, and is currently $95.39 million as of their latest financial filing in 2024.

How has BioLife Solutions' book value per share changed over the last 10 years?

Over the last 10 years, BioLife Solutions' book value per share changed from 0.98 in 2014 to 7.52 in 2024, a change of 670.0%.

Remove Ads

Related Companies

This page (NASDAQ:BLFS) was last updated on 4/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioLife Solutions (BLFS) Financials

Frequently Asked Questions About BioLife Solutions' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioLife Solutions (BLFS) Financials

Annual Income Statements for BioLife Solutions

Quarterly Income Statements for BioLife Solutions

Annual Cash Flow Statements for BioLife Solutions

Quarterly Cash Flow Statements for BioLife Solutions

Annual Balance Sheets for BioLife Solutions

Quarterly Balance Sheets for BioLife Solutions

Annual Metrics and Ratios for BioLife Solutions

Quarterly Metrics and Ratios for BioLife Solutions

Frequently Asked Questions About BioLife Solutions' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools